pdufa.bio
Home › Decisions › MRK 2026-06-18

MRK FDA decision — Jun 18, 2026

✓ APPROVED

Merck & Company Inc. — CAPVAXIVE (Pneumococcal 21-valent Conjugate · Pneumococcal Disease.

Run-up into the decision (T-120 → T+5)

PDUFA 6/18/26$123.93$105.261/1/26
Daily close, T-120 (1/1/26) through T+5. Run-up high $123.93 on 2/26/26, low $105.26 on 1/7/26 (T-120 to T-1). FDA decision 6/18/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-18
OutcomeApproved
Drug / candidateCAPVAXIVE (Pneumococcal 21-valent Conjugate
CompanyMerck & Company Inc.
120-day run-up (T-120→T-1)+8.4%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio